Literature DB >> 7460196

Phase I evaluation of divided-dose vinblastine sulfate.

P Schulman, D R Budman, V Vinciguerra, T J Degnan.   

Abstract

The known pharmacokinetics of vinblastine sulfate given by intermittent bolus dictate alternate dose schedules for prolonging the therapeutic levels. Herein, we have tested a divided dose schedule which shows out-patient feasibility, manageable toxicity, and encouraging responses.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7460196     DOI： 10.1007/bf00578565

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  7 in total

1.  Pharmacokinetics and metabolism of vinblastine in humans.

Authors:  R J Owellen; C A Hartke; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

2.  Periwinkle alkaloids and the platelet-count.

Authors:  J H Robertson; G M McCarthy
Journal:  Lancet       Date:  1969-08-16       Impact factor: 79.321

3.  Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response.

Authors:  J N Bickers; E A Gehan; E J Freireich; C A Coltman; H E Wilson; J S Hewlett; W J Stuckey; E J Van Slyck
Journal:  Arch Intern Med       Date:  1974-02

4.  Definition of the cell cycle segment with special sensitivity to vinblastine.

Authors:  A M Chirife; G P Studzinski
Journal:  Proc Soc Exp Biol Med       Date:  1978-02

5.  Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo.

Authors:  W R Bruce; B E Meeker; F A Valeriote
Journal:  J Natl Cancer Inst       Date:  1966-08       Impact factor: 13.506

Review 6.  Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

Authors:  R W Dyke; R L Nelson
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

7.  Management of trials in the development of cancer chemotherapy.

Authors:  C J Williams; S K Carter
Journal:  Br J Cancer       Date:  1978-03       Impact factor: 7.640
  7 in total
  1 in total

1.  Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine.

Authors:  J A Young; S B Howell; M R Green
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.